Modern ART has now achieved the goal of maintaining HIV RNA suppression with minimum
drug-related toxicities. Indeed, in high-income settings, the main health issues in adult …

In almost 4 decades since the start of the HIV epidemic, the world has witnessed an
unprecedented evolution of this disease from a debilitating and rapidly fatal syndrome to a …

Importance Cardiovascular disease (CVD) is increased in people with HIV (PWH) and is
characterized by premature noncalcified coronary plaque. In the Randomized Trial to …

Importance Cardiovascular disease (CVD) is increased among people with HIV (PWH), but
little is known regarding the prevalence and extent of coronary artery disease (CAD) and …

Although people with HIV are living longer, as they age they remain disproportionately
burdened with multimorbidity that is exacerbated in resource-poor settings. The geroscience …

Background In addition to traditional cardiovascular (CV) risk factors, antiretroviral therapy,
lifestyle, and human immunodeficiency virus (HIV)-related factors may contribute to future …

Clonal hematopoiesis of indeterminate potential (CHIP), the clonal expansion of myeloid
cells with leukemogenic mutations, results in increased coronary artery disease (CAD) risk …

Prevention of CVD among the aging population of people with controlled, but chronic, HIV is
vital. Data exploring primary prevention in this context are thus far limited. The Randomized …

Human immunodeficiency virus (HIV) infection represents a major cardiovascular risk factor,
and the cumulative cardiovascular disease (CVD) burden among aging people living with …

Abstract The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) is the largest
study of cardiovascular disease in human immunodeficiency virus. Enrolling 7770 …